Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

COPD symptoms tend to worsen with outdoor air pollution: US study

People with chronic obstructive pulmonary disease (COPD) tend to experience worsening symptoms at times when levels of pollution in their community are higher, a new U.S. study indicates. “Our findings are consistent with a growing number of studies reporting adverse effects of community-level exposure to air pollution on respiratory…

Prompt treatment with Breztri Aerosphere lowers exacerbation risk

Prompt treatment with Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) after a moderate or severe chronic obstructive pulmonary disease (COPD) exacerbation can lower the risk of a future worsening episodes. That’s according to data by AstraZeneca, which markets Breztri Aerosphere, in the late-breaking abstract, “Exacerbations and Real-world Outcomes…

Emphysema patients who smoke quicken lung damage: Study

Among people with chronic obstructive pulmonary disease (COPD) who have emphysema, individuals who continue to smoke after being diagnosed tend to have faster progression of lung damage, a recent study reported. According to researchers, these findings imply quitting smoking may help slow lung disease progression. “We were able to…

Ensifentrine Lowers Exacerbation Rate Across Variety of COPD Patients

Ensifentrine, an inhaled treatment being developed by Verona Pharma, lowered the rate of exacerbations, or episodes of sudden disease worsening, across all subgroups of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) in the Phase 3 ENHANCE-2 trial. “We are very encouraged by the meaningful and consistent reductions…

Anti-inflammatory DMX-700 Found to Reduce Lung Injury in COPD Mice

An experimental anti-inflammatory medication called DMX-700, being developed by Dimerix for chronic obstructive pulmonary disease (COPD), was found to substantially reduce lung injury in a mouse model of the disease. “DMX-700 has demonstrated some very encouraging pre-clinical data,” Nina Webster, PhD, CEO and managing director of Dimerix,…

Fibrinogen Protein Levels May Help Predict Exacerbation Outcomes

Levels of the protein fibrinogen in the blood can be used to assess inflammation and the risk of non-invasive ventilation failure during acute exacerbations in people with chronic obstructive pulmonary disease (COPD), according to a new study. Fibrinogen is an inflammation-associated protein that is known as a biomarker for…